Dr. Angelo Antonini, Dr. Matteo Bologna, Roy Jones, Dr. Fidias Leon-Sarmiento, and Dr. Fabrizio Stocchi, will help guide company as they advance central nervous system research

Mr. Riley to Lead Corporate Development Efforts as Company Targets New Clinical Applications for its Proprietary, FDA-Cleared Blink Reflex Technology

CNS drug developers have to focus on physical safety and efficacy first, especially when developing products for rare disorders or diagnoses that are often unresponsive to other therapies. Although these products rarely have notable CNS mediated side effects, they fall under the FDA's requirement for an abuse potential assessment because they cross the blood-brain barrier.